Semnur Pharmaceuticals has completed a Phase 3 study for the treatment of lumbar radicular pain, commonly known as sciatica meeting primary and important key secondary endpoints and has received fast track status from the FDA for the novel injectable gel formulation (SP-102) in development. Learn more
SP-102 is the first non-opioid novel injectable gel formulation in development for the treatment of lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents or particulates. Learn more
We are currently advancing a portfolio of non-opioid novel injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapies. Learn more